Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
Public ClinicalTrials.gov record NCT06632951. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Randomized Study of Livmoniplimab in Combination With Budigalimab Versus Chemotherapy in Subjects With Metastatic Urothelial Carcinoma
Study identification
- NCT ID
- NCT06632951
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Interventions
- Budigalimab Drug
- Docetaxel Drug
- Gemcitabine Drug
- Livmoniplimab Drug
- Paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 19, 2025
- Primary completion
- Feb 28, 2027
- Completion
- Jul 31, 2028
- Last update posted
- Aug 10, 2025
2025 – 2028
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group - Springdale /ID# 270290 | Springdale | Arkansas | 72762 | — |
| University of California San Francisco - Mission Bay /ID# 270289 | San Francisco | California | 94158 | — |
| Yale University School of Medicine /ID# 270449 | New Haven | Connecticut | 06510 | — |
| Medical Oncology Hematology Consultants /ID# 271347 | Newark | Delaware | 19713 | — |
| Florida Cancer Specialists - North /ID# 271215 | St. Petersburg | Florida | 33705 | — |
| Icahn School of Medicine at Mount Sinai /ID# 270272 | New York | New York | 10029 | — |
| University Hospitals Cleveland Medical Center /ID# 271010 | Cleveland | Ohio | 44106 | — |
| The Ohio State University /ID# 271349 | Columbus | Ohio | 43210 | — |
| SCRI Oncology Partners /ID# 270439 | Nashville | Tennessee | 37203 | — |
| Texas Oncology - Austin Central /ID# 271284 | Austin | Texas | 78731 | — |
| Utah Cancer Specialist /ID# 270810 | Salt Lake City | Utah | 84124 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06632951, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 10, 2025 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06632951 live on ClinicalTrials.gov.